The Italian LGMD registry : relative frequency , clinical features , and differential diagnosis

Introduction Limb girdle muscular dystrophies (LGMDs) are characterized by high molecular heterogeneity, clinical overlap, and a paucity of specific biomarkers. However, their molecular definition is fundamental for prognostic and therapeutic purposes. Methods We created an Italian LGMD registry that included 370 molecularly defined patients. We reviewed detailed retrospective and prospective data and compared each LGMD subtype for differential diagnosis purposes. Results LGMD2A and 2B are the most frequent forms in Italy. The ages at disease onset, clinical progression, and cardiac and respiratory involvement can vary greatly between each LGMD subtype. In a set of extensively studied patients, targeted next-generation sequencing (NGS) identified mutations in 36.5% of cases. Conclusion: Detailed clinical characterization combined with muscle tissue analysis is fundamental to guide differential diagnosis and to address molecular tests. NGS is useful for diagnosing forms without specific biomarkers, although, at least in our study cohort, several LGMD disease mechanisms remain to be identified.

[1]  V. Straub,et al.  The Classification, Natural History and Treatment of the Limb Girdle Muscular Dystrophies , 2015, Journal of neuromuscular diseases.

[2]  I. Nelson,et al.  Detection of TRIM32 deletions in LGMD patients analyzed by a combined strategy of CGH array and massively parallel sequencing , 2014, European Journal of Human Genetics.

[3]  G. Comi,et al.  MotorPlex provides accurate variant detection across large muscle genes both in single myopathic patients and in pools of DNA samples , 2014, Acta neuropathologica communications.

[4]  G. Comi,et al.  Revised Genetic Classification of Limb Girdle Muscular Dystrophies. , 2014, Current molecular medicine.

[5]  L. Kunkel,et al.  A defect in the RNA-processing protein HNRPDL causes limb-girdle muscular dystrophy 1G (LGMD1G). , 2014, Human molecular genetics.

[6]  V. Nigro,et al.  Genetic basis of limb-girdle muscular dystrophies: the 2014 update , 2014, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[7]  D. MacArthur,et al.  Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan. , 2013, American journal of human genetics.

[8]  L. Køber,et al.  Anoctamin 5 muscular dystrophy in Denmark: prevalence, genotypes, phenotypes, cardiac findings, and muscle protein expression , 2013, Journal of Neurology.

[9]  C. Angelini,et al.  Next-Generation Sequencing Identifies Transportin 3 as the Causative Gene for LGMD1F , 2013, PloS one.

[10]  C. Bruno,et al.  Limb-girdle muscular dystrophy with α-dystroglycan deficiency and mutations in the ISPD gene , 2013, Neurology.

[11]  M. Hauser,et al.  Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy , 2012, Nature Genetics.

[12]  K. Bushby,et al.  Diagnosis and management of the limb girdle muscular dystrophies , 2009, Practical Neurology.

[13]  K. Bushby,et al.  Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. , 2009, Brain : a journal of neurology.

[14]  C. Angelini,et al.  Frequency of LGMD gene mutations in Italian patients with distinct clinical phenotypes , 2009, Neurology.

[15]  K. Bushby,et al.  Limb-girdle muscular dystrophies. , 2008, Current opinion in neurology.

[16]  M. Schwartz,et al.  High prevalence and phenotype–genotype correlations of limb girdle muscular dystrophy type 2I in Denmark , 2006, Annals of neurology.

[17]  M. Zatz,et al.  Calpains and disease. , 2005, The New England journal of medicine.

[18]  K. Bushby,et al.  The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations , 2005, Human mutation.

[19]  I. Nonaka,et al.  Calpain 3 gene mutations: genetic and clinico-pathologic findings in limb-girdle muscular dystrophy , 2001, Neuromuscular Disorders.

[20]  S. Limborska,et al.  High incidence of 550delA mutation of CAPN3 in LGMD2 patients from Russia , 2000, Human mutation.

[21]  M. Passos-Bueno,et al.  Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G. , 1999, American journal of medical genetics.

[22]  G. Comi,et al.  Sarcoglycan deficiency in a large Italian population of myopathic patients , 1998, Acta Neuropathologica.

[23]  J. Beckmann,et al.  Characterization of monoclonal antibodies to calpain 3 and protein expression in muscle from patients with limb-girdle muscular dystrophy type 2A. , 1998, The American journal of pathology.

[24]  J. Beckmann,et al.  Limb-girdle muscular dystrophy in Guipúzcoa (Basque Country, Spain). , 1998, Brain : a journal of neurology.

[25]  J. Beckmann,et al.  Calpain-3 deficiency causes a mild muscular dystrophy in childhood. , 1997, Neuropediatrics.

[26]  G. van Ommen,et al.  The clinical spectrum of limb girdle muscular dystrophy. A survey in The Netherlands. , 1996, Brain : a journal of neurology.

[27]  Margaret A. Johnson,et al.  Dystrophin in skeletal muscle II. Immunoreactivity in patients with Xp21 muscular dystrophy , 1989, Journal of the Neurological Sciences.

[28]  F. J. Nattrass,et al.  On the classification, natural history and treatment of the myopathies. , 1954, Brain : a journal of neurology.

[29]  R. Griggs,et al.  Evidence-based guideline summary: Diagnosis and treatment of limb-girdle and distal dystrophies , 2014, Neurology.

[30]  F. Norwooda,et al.  EFNS guideline on diagnosis and management of limb girdle muscular dystrophies , 2007 .

[31]  J. Beckmann,et al.  Disease taxonomy--monogenic muscular dystrophy. , 1999, British medical bulletin.

[32]  J. Walton PROGRESSIVE MUSCULAR DYSTROPHY. , 1964, Postgraduate medicine.